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MDR1 siRNA loaded hyaluronic
acid-based CD44 targeted nanoparticle
systems circumvent paclitaxel resistance
in ovarian cancer
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& Zhenfeng Duan1
1Sarcoma Biology Laboratory, Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital and Harvard
Medical School, Boston, MA 02114, 2Department of Gynaecology and Obstetrics, The Third Affiliated Hospital of Zhengzhou
University, Zhengzhou 450052, Henan Province, China, 3Department of Pharmaceutical Sciences, School of Pharmacy,
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Development of multidrug resistance (MDR) is an almost universal phenomenon in patients with ovarian
cancer, and this severely limits the ultimate success of chemotherapy in the clinic. Overexpression of the
MDR1 gene and corresponding P-glycoprotein (Pgp) is one of the best known MDR mechanisms. MDR1
siRNA based strategies were proposed to circumvent MDR, however, systemic, safe, and effective targeted
delivery is still a major challenge. Cluster of differentiation 44 (CD44) targeted hyaluronic acid (HA) based
nanoparticle has been shown to successfully deliver chemotherapy agents or siRNAs into tumor cells. The
goal of this study is to evaluate the ability of HA-PEI/HA-PEG to deliver MDR1 siRNA and the efficacy of
the combination of HA-PEI/HA-PEG/MDR1 siRNA with paclitaxel to suppress growth of ovarian cancer.
We observed that HA-PEI/HA-PEG nanoparticles can efficiently deliver MDR1 siRNA into MDR ovarian
cancer cells, resulting in down-regulation of MDR1 and Pgp expression. Administration of HA-PEI/
HA-PEG/MDR1 siRNA nanoparticles followed by paclitaxel treatment induced a significant inhibitory
effect on the tumor growth, decreased Pgp expression and increased apoptosis inMDR ovarian cancer mice
model. Our findings suggest that CD44 targetedHA-PEI/HA-PEG/MDR1 siRNAnanoparticles can serve as
a therapeutic tool with great potentials to circumvent MDR in ovarian cancer.
O
varian cancer is a lethal gynecological malignancy and ranks as the fifth leading cause of cancer death
among women. It is estimated that about 21,980 women will be diagnosed with ovarian cancer and
14,270 patients will die in the United States in 20141,2. Since most early stage ovarian cancer is generally
asymptomatic, it is difficult to recognize this disease until it is at an advanced stage. Approximately 75 percent of
women diagnosed with ovarian cancer will present with advanced disease. The overall five-year survival rate of
patients diagnosed at stage III and IV of this disease is 32% and 18%3,4. Recommended management of advanced
disease usually consists of primary cytoreductive surgery followed by paclitaxel-platinum combination chemo-
therapy. Although the response rate to paclitaxel and platinum is up to 80% and a great improvement of median
overall survival has been made in patients treated with chemotherapy, unfortunately, 50–75% of patients with
advanced ovarian cancer will ultimately relapse due to the development of multidrug resistance (MDR)4–6. MDR
remains one of the most significant challenges in our endeavor to cure ovarian cancer4,7–9.
MDR is a phenomenon in which, after exposure of the tumor to a specific chemotherapy drug, tumor cells
eventually develop resistance to that chemotherapy or to a wide range of functionally and structurally unrelated
chemotherapeutic agents8,10. MDR can be either intrinsic or acquired through exposure over time to anticancer
drugs, and the mechanisms of MDR are complicated7,11. Overexpression of MDR gene 1 (MDR1) and the
corresponding ATP-binding cassette (ABC) transporter P-glycoprotein (Pgp) is one of the best characterized
ways MDR can develop8,10,12. Pgp is an energy-dependent drug efflux pump, whose function is to export chemo-
therapy drugs from the inside of cells to the outside. Overexpression of Pgpwill result in a decrease of intracellular
accumulation of chemotherapeutic drugs, and subsequently induce MDR in tumor cells to anticancer drugs8,13.
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ovarian cancer8,14,15. It has been reported that MDR1/Pgp may have
useful predictive value in determining the clinical outcome of
patients with advanced ovarian cancer16–18. The expression level of
MDR1 in patients that do not respond to chemotherapy was signifi-
cantly higher than in patients that respond to chemotherapy18. The
overall survival time was statically shortened in patients with tumors
with highMDR1/Pgp expression levels18. New experimental evidence
has demonstrated that the epithelial-mesenchymal transition (EMT)
has the potential to confer stem-cell like properties to a subpopula-
tion of cancer cells, leading to the onset of resistance to anticancer
drugs19,20. In addition, studies have also suggested that evasion of
apoptosis, activation ofDNA repair, activation of detoxifying system,
and changes in drug transport may contribute to the development of
MDR20.
In order to improve the outcome of chemotherapy, strategies to
circumvent MDR have been studied extensively in recent years. One
of the promising approaches to overcoming MDR is by inhibiting
MDR1 expression by using RNA interference (RNAi) technologies
with either small interfere RNA (siRNA) or small hairpin RNA
(shRNA). We and others previously have demonstrated that knock-
ing down MDR1 expression by transfecting MDR cells with MDR1
siRNA using Lipofectamine or nanoparticles can restore sensitivity
to paclitaxel and other Pgp substrates21–24. However, targeted, sys-
temic, effective, and safe delivery of siRNA to a specific tumor site in
vivo is still a major obstacle in developing siRNA as a clinically viable
method to treat cancer patients with MDR.
Hyaluronic acid (HA) is an anionic, non-sulfated glycosaminogly-
can. HA plays an important role in cell growth, proliferation and
adhesion25,26. Cluster of differentiation 44 (CD44), a family of multi-
functional trans-membrane glycoproteins, has been demonstrated to
interact with HA at the N terminus of its extracellular domain, and
therefore serves as a major cell surface receptor for HA25. The bind-
ing of HA to CD44 is important for its biological activities, including
cell adhesion, migration, invasion, proliferation, and angiogenesis25,26.
The presence of high expression levels of CD44 was considered to be
associated with drug resistance during ovarian cancer metastasis and is
an unfavorable prognosis or survival marker in ovarian cancer26,27. Co-
overexpression of CD44 and Pgp has been associated with drug res-
istance and progression in different tumor cells including ovarian
cancer28–30.
Previously, HA-based chemotherapy drugs have shown antitumor
activity in vivo31. CD44 targeted HA-based nanoparticles have also
been shown to successfully deliver siRNA into tumor cells and result
in specific mRNA knockdown in lung cancer xenograft models32,33.
In the current study, we studied the efficiency of siRNA delivery of
MDR1 siRNA loaded HA-PEI/HA-PEG CD44 targeted nanoparti-
cles and their effects on circumventing drug resistance in an MDR
ovarian cancer model in vitro and in vivo. This is the first study to
examine the potential for CD44 targeted HA-PEI/HA-PEG-based
nanoparticle to deliver MDR1 siRNA to tumor cells in vivo to over-
come drug resistance. As MDR1 is the major mechanism for pacli-
taxel resistance, the combination of MDR1 siRNA CD44 targeted
nanoparticle and paclitaxel hold great potential to increase paclitaxel
sensitivity/efficacy and overcome MDR in ovarian cancer treatment.
Results
Ovarian cancer cell lines and tumor tissues expressed high levels
of CD44. HA has high specificity and affinity for the CD44 receptor
which is overexpressed on the cell surface of numerous tumors25. CD44
enhances the ability of HA based nanoparticles to deliver siRNA and/or
drugs to the specific tumor sites33. We first determined the expression
level of CD44 in ovarian cancer drug sensitive and resistant cell lines
SKOV-3 and SKOV-3TR. We showed that both SKOV-3 parental sen-
sitive cell line and chemoresistant cell line SKOV-3TR displayed high
expression of CD44, while SKOV-3TR cells showed higher expression
level of CD44 than SKOV-3 cells (Fig. 1A). Relative expression of CD44
was analyzed by densitometry and shown in Fig. 1B. However, only
chemoresistant cells SKOV-3TR showed overexpression of Pgp which
is consistent with previous studies that show that overexpression of
Pgp is one of the major mechanisms of MDR in SKOV-3TR cell line
(Fig. 1A and B). Immunofluorescence studies further confirmed that
CD44 could be detected in both sensitive and resistant cells (Fig. 1C)
and in ovarian cancer tissues (Fig. 1D). In addition, the expression
levels of CD44 and Pgp were examined in various ovarian cancer cell
lines, including drug sensitive and resistant ovarian cancer cell lines,
and the results were shown in the Fig. S1.
Characterization of MDR1 siRNA loaded HA-PEI/HA-PEG nano-
particles. The particle size and zeta potentials ofMDR1 siRNA loaded
HA-PEI/HA-PEG self-assemble nanoparticles were examined using
the Zetasizer Nano-SH instrument. The mean Z-average particle size
(nm) of HA-PEI/HA-PEG/MDR1 siRNA nanoparticles was 173.3 6
13.7 nm (Fig. 2A). As shown in Fig. 2B, a negative surface charge was
presented by HA-PEI/HA-PEG/MDR1 siRNA nanoparticles. The zeta
potential of nanoparticles was 222.5 6 0.44 mV, despite the presence
of cationic polymer, PEI. Representative TEM image suggested a dark
core for the nanoparticles, which may be attributed to the high con-
trast arising from the uranyl acetate stained MDR1 siRNA loaded in
the core of the HA-PEI/HA-PEG nanoparticles (Fig. 2C).
One of the key questions concerning nanocarriers is the safety
for future clinical application. Therefore, the cytotoxicity of HA-
EPI/HA-PEG/MDR1 siRNA for SKOV-3TR cells was evaluated by
MTT assay prior to gene silencing tests. SKOV-3TR cells were plated
in 96-well plate and incubated withHA-PEI/HA-PEG/MDR1 siRNA
for 6 h on the following day. The cells were subsequently incubated
with fresh media for another 48 h and MTT assay was performed.
The results showed 80% of the cells remained viable after treatment
with HA-PEI/HA-PEG/MDR1 siRNA for 6 h at the concentration of
600 mg/mL, while in current study, the highest concentration of HA-
PEI/HA-PEG used for transfection was 170 mg/mL. This finding
suggested that there was no apparent cytotoxicity of HA-PEI/HA-
PEG/MDR1 siRNA during transfection and the cells could tolerate it
well (Fig. 2D). Based on the results as described above, schematic
illustration of HA-PEI/HA-PEG/MDR1 siRNA nanoparticle was
shown in Fig. 2E. The structure of nanoparticle has a core–shell
architecture with a PEG corona. The PEG corona surrounds the
hydrophilic HA shell with the core containing the positively charged
PEI complexed with the negatively charged MDR1 siRNA.
Suppression efficacy of target gene usingMDR1 siRNA loaded HA-
PEI/HA-PEG CD44 targeted nanoparticles. In order to ascertain if
theMDR1 siRNA was delivered and released from HA-PEI/HA-PEG
CD44 targeted nanoparticle and still maintained its functional activity
to knockdown gene expression in vitro, the RNA was extracted from
SKOV-3TR cells after transfected with HA-PEI/HA-PEG/MDR1
siRNA. Real-time PCR assay was conducted and the expression
level of MDR1 targeted gene was assessed. We showed that HA-
PEI/HA-PEG/MDR1 siRNA nanoparticle transfected cells showed
significantly decreased levels of MDR1 expression as determined
by relative quantitative analysis using 22DDCt method. However, no
significant changes of MDR1 expression were observed in cells
incubated with either MDR1 siRNA alone or HA-PEI/HA-PEG
CD44 targeted non-specific siRNA. In addition, the level of decrease
in MDR1 expression was correlated with the dosage of MDR1 siRNA
loaded nanoparticle in a dose dependent manner. Indeed, the
expression levels of MDR1 in cells transfected with 45 nM, 90 nM
and 180 nM MDR1 siRNA decreased by 73.9%, 48.5% and 39.6%,
respectively, when compared with the SKOV-3TR cells without
treatment (Fig. 3A). Similar results were found in OVCAR8TR cells
(another MDR ovarian cancer cell line, data not shown).
The human MDR1 gene encodes an integral membrane protein,
Pgp. Therefore, expression levels of Pgp in cells transfected with
CD44 targetedHA-PEI/HA-PEG/MDR1 siRNAwere also evaluated.
www.nature.com/scientificreports
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The expression level of Pgp significantly decreased in SKOV-3TR
cells transfected with HA-PEI/HA-PEG/MDR1 siRNA nanoparticles.
Western blot analysis revealed that this inhibition was also dose-
dependent (Fig. 3B). Further densitometric quantification data from
Western blot results are shown in Fig. 3C. The expression level of Pgp
in cells transfected with 45 nM, 90 nM and 180 nM MDR1 siRNA
decreased by 46.4%, 41.1% and 31.4%, respectively, when compared
with that the cells without transfection. Similar results were found in
OVCAR8TR cells (Fig. S2). Taken together, these data, demonstrated
thatMDR1 siRNA was not only delivered and released fromHA-PEI/
HA-PEG CD44 targeted nanoparticle but also retained its activity to
efficiently silence MDR1 gene and Pgp expression.
Combination of HA-PEI/HA-PEG/MDR1 siRNA CD44 targeted
nanoparticle and paclitaxel treatment inhibited resistant ovarian
cancer tumors growth. After confirming that HA-PEI/HA-PEG
CD44 targeted nanoparticles can efficiently deliver MDR1 siRNA
into MDR cells and result in down-regulation of MDR1 and Pgp
expression, we next evaluated antitumor efficacy of the combination
of HA-PEI/HA-PEG/MDR1 siRNA CD44 targeted nanoparticles
and paclitaxel in ovarian cancer tumor-bearing nudemice. The treat-
ment scheme is shown in Fig. 4A. Our in vivo study showed that the
average tumor volume in mice administrated with the combination
of HA-PEI/HA-PEG/MDR1 siRNA CD44 targeted nanoparticle and
paclitaxel was significantly smaller than that observed in control groups
(Fig. 4B). Tumor volume of mice treated with paclitaxel alone was
approximately 3-fold higher than in mice treated with combined HA-
PEI/HA-PEG/MDR1 siRNA CD44 targeted nanopartricle and pacli-
taxel, which could reflect an increased chemosensitivity to paclitaxel
in mice treated with HA-PEI/HA-PEG/MDR1 siRNA. However,
changes in tumor volume in mice treated with either the combina-
tion of HA-PEI/HA-PEG/non-specific siRNA CD44 targeted nano-
particle and paclitaxel or the combined naked MDR1 siRNA and
paclitaxel was similar to that with paclitaxel treated alone in this
ovarian cancer MDR model (Fig. 4B). Representative images of
mice and tumors form each group were shown in Fig. 4C.
In comparison, we also tested the effects of the combination of
HA-PEI/HA-PEG/MDR1 siRNA CD44 targeted nanoparticle and
paclitaxel on tumor growth in drug sensitive SKOV-3 (not express
MDR1 and Pgp) xenograft mice model that did not highly express
Pgp. We demonstrated that administration of HA-PEI/HA-PEG/
MDR1 siRNA CD44 targeted nanoparticle followed by paclitaxel
treatment had similar effects on tumor growth as the control group
of tumor treated with saline and paclitaxel in SKOV-3 xenograft
model (Fig. 4D). These data suggest that increased chemosensitivity
in combination of HA-PEI/HA-PEG MDR1 siRNA CD44 targeted
nanoparticles and paclitaxel treatment in SKOV-3TR is the result of
down-regulation ofMDR1 and Pgp expression, and reversal of pacli-
taxel resistance. Additionally, on the basis of animal body weight and
mortality, no significant toxicity was noticed and the animals appeared
to have tolerated HA-PEI/HA-PEG nanoparticles well when HA-PEI/
HA-PEG/MDR1 siRNA and HA-PEI/HA-PEG/non-specific siRNA
were administered (data not shown).
Combined HA-PEI/HA-PEG/MDR1 siRNA CD44 targeted nano-
particle and paclitaxel treatment decreased Pgp expression and
increased apoptosis in MDR cells. In order to determine the under-
lying mechanism of how chemosensitivity to paclitaxel increased in
the xenograft MDR ovarian cancer model in mice, the proteins of
SKOV-3TR tumor mass were extracted to further determine the
expression levels of Pgp and CD44. We showed by western blot
that administration of the combination of HA-PEI/HA-PEG/MDR1
Figure 1 | Expression of CD44 and Pgp in ovarian cancer cells and tumor tissues. (A). Expression level of CD44 and Pgp in ovarian cancer resistant cell
line SKOV-3TR and parental sensitive cell line SKOV-3 determined byWestern Blot. (B). Relative expression of CD44 and Pgp from (A)were analyzed by
densitometry. Data are presented as means 6 SEM and analyzed using Student’s t-test. Statistical comparisons between SKOV-3TR and SKOV-3 cells
are displayed: ** P , 0.01,*** P , 0.005. (C). Expression of CD44 and Pgp in SKOV-3TR and SKOV-3 cells evaluated by immunofluoresecence.
CD44 and Pgp proteins were stained using secondary antibody conjugated with Alexa Fluor 594 (Red). Nuclei were stained withDAPI nuclear dye (Blue).
(D). Expression of CD44 in ovarian cancer tissues. Representative images of IHC results were shown.
www.nature.com/scientificreports
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siRNA CD44 targeted nanoparticles and paclitaxel dramatically de-
creased Pgp expression inMDR cells frommice. These in vivo data are
consistent with the findings observed in vitro (Fig. 5A). Immunohis-
tochemistry analysis of HA-PEI/HA-PEG/MDR1 siRNA CD44 tar-
geted nanoparticle on Pgp staining in ovarian cancer MDR tumor
tissues further confirmed downregulation of Pgp as compared with
either saline alone, MDR1 alone or HA-PEI/HA-PEG/non-specific
siRNA nanoparticle treatment (Fig. 5B). Additionally CD44 expres-
sions were detected in ovarian cancer tumor tissues in xenograft
model, consistent with the in vitro results (Fig. 5B).
We used TUNEL apoptosis assay on tumor sections to test whether
the tumor suppression with combination HA-PEI/HA-PEG/MDR1
siRNA CD44 targeted nanoparticle and paclitaxel treatment is related
to induced apoptosis in treated tumor. As shown in Fig. 6, the apop-
tosis level was enhanced in theMDR ovarian tumor tissues in animals
administrated with the combination of HA-PEI/HA-PEG/MDR1
siRNA and paclitaxel. However, the apoptosis level was not signifi-
cant in tumor sections for animals that received either saline alone,
MDR1 alone or HA-PEI/HA-PEG/non-specific siRNA nanoparticle
followed by paclitaxel treatment.
Discussion
Paclitaxel is one of the most effective chemotherapeutic agents for
ovarian cancer and is a first line drug used in the treatment of this
disease; however, the eventual development of resistance to paclitaxel
therapy occurs almost in all patients8,9,12. Overcoming Pgp-basedMDR
is one possible way to achieving greater effect from chemotherapy.
Although a wide range of compounds that interact with Pgp and block
drug efflux have been reported to reverse the MDR phenotype10,34,
these compounds are nonspecific, toxic and have low potency at doses
patients can tolerate34. For the majority of these compounds, clinical
toxicities associated with their use at concentrations required to inhibit
Pgp have precluded their widespread use for overcome MDR10,35. The
results from many clinical trials showed almost no survival benefits by
using these MDR reversing agents of Pgp inhibitors such as verapamil,
cyclosporine-A, PSC-833 (Valspodar) and VX-710 (Biricodar) in dif-
ferent cancer types including ovarian cancer, highlighting a crucial
need for an alternative specific, safe and effective strategy to overcome
MDR36–40. In this regard, the utility of nanotechnology may lead to
innovative methods for effective and targeted delivery of siRNA-based
therapies to circumvent MDR.
Our results indicate that HA-PEI/HA-PEG CD44 targeted nano-
particles can efficiently deliver MDR1 siRNA into MDR ovarian
cancer cells both in vitro and in vivo. We demonstrated that HA-
PEI/HA-PEG CD44 targeted nanoparticles loaded with MDR1
siRNA efficiently down-regulate the expression of MDR1 and Pgp,
inhibit the functional activity of Pgp, and subsequently increase
MDR cell sensitivity to paclitaxel. Administration of HA-PEI/HA-
Figure 2 | Characterization of MDR1 siRNA loaded HA-PEI/HA-PEG nanoparticles. (A). The mean of Z-average particle size of HA-PEI/HA-PEG/
MDR1 siRNAnanoparticles was 173.36 13.7 nm. (B). The zeta potential of nanoparticles was222.56 0.44 mV. (C). Representative TEM image ofHA-
PEI/HA-PEG/MDR1 siRNA nanoparticles was shown. The dark core was exhibited in the central of nanoparticles. (D). The cytotoxicity of HA-PEI/HA-
PEG/MDR1 siRNA nanoparticles in SKOV-3TR cells. (E). Schematic illustration of HA-PEI/HA-PEG MDR1 siRNA nanoparticle showed that the
structure of nanoparticle was core–shell–corona. The PEG corona surrounded HA shell, and positive core contained PEI as well asMDR1 siRNA.
www.nature.com/scientificreports
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PEG/MDR1 siRNA nanoparticle followed by paclitaxel treatment
induced a significant inhibitory effect on the tumor growth in MDR
ovarian cancer xenograft mouse model as compared with control
groups. As albumin-bound paclitaxel nanoparticles (Abraxane) have
been approved by the FDA for the treatment of metastatic breast
cancer and non-small cell lung cancer (NSCLC)41,42, and the limited
supply of the first FDA-approved nano-drug Doxil in recent years43,
the results from our current study signifies that CD44-targeted HA-
PEI/HA-PEG nanoparticle platform can be an effective delivery sys-
tem for siRNA-based anticancer therapeutics in treating drug resistant
ovarian cancer.
Among various nanoparticles used for siRNA delivery for sys-
temic administration, HA-PEI/HA-PEG nanoparticle possesses
unique properties. HA is a naturally occurring polyanionic biopoly-
mer and is one of themajor components of the extracellularmatrix of
connective tissues and present in synovial fluid of joints and in the
vitreous body44. HA has been extensively investigated for several
biomedical applications, such as tissue engineering and drug and
gene delivery systems, because of its biocompatibility, biodegradabil-
ity, and readily modifiable chemical structure44. The present work
showed HA-PEI/HA-PEG nanoparticles not only hold high effi-
ciency ofMDR1 siRNA encapsulation and delivery into tumor cells,
but also displayed no significant cytotoxicity.
Another advantage of HA-PEI/HA-PEG nanoparticle is the poten-
tial of increased cellular uptake of MDR1 siRNA in MDR ovarian
cancer cells via targeted delivery through HA-CD44 receptor inter-
action. CD44 is a receptor for HA and has been shown to play critical
roles in ovarian cancer stem cells, metastasis and drug resistance25,45.
CD44 is an acidic glycoprotein which binds HA with a particularly
high affinity. The binding of HA to CD44 triggers direct cross-signal-
ing between different signaling pathways including HER2, Src kinase
and ERK, and CD44 is thought to be involved in increased motility,
adhesion, and invasion of cancer cells as well as differentiation of
cancer stem cell25,44,45. Higher level of CD44 expression has been
shown in ovarian cancer compared with benign and borderline
tumors46. Several studies have suggested that cancer patients with
CD44 positive tumors have a significantly shorter disease-free sur-
vival than patients with CD44 negative tumors46. CD44 monoclonal
antibody treatment has been shown to inhibit ovarian cancer cell
motility but not invasion47. Anti-CD44 antibody has also been shown
to decrease the number of total peritoneal ovarian cancer metastases
in mice47. In addition, previous studies have shown that in ovarian
cancer cells, paclitaxel-HA conjugate interacted with CD44, entered
the cells through a receptor-mediated mechanism, and exerted a
concentration-dependent inhibitory effect on tumor cell growth48.
After intra-peritoneal (IP) administration in mice, HA bioconjugate
distributed uniformly within the peritoneal cavity, was well tolerated,
and not associated with local toxicity48. HA-based CD44 targeted
nanoparticle has been used for both either chemotherapy drug or
siRNA delivery31,32,48. Overexpression of CD44 enhances tumor cell
growth, cancer stem cell differentiation, drug resistance, and meta-
stases25,30,49. A more recent study showed CD44 is highly overex-
Figure 3 | Expression level of target gene in SKOV-3TR cells transfected with HA-PEI/HA-PEG/MDR1 siRNA nanoparticles. (A). Expression level of
MDR1 mRNA in HA/PEI/HA-PEG/MDR1 siRNA transfected cells. MDR1 mRNA expression level was determined by real-time PCR and the data
was analyzed using 22DDCt method. (B). Influence of HA-PEI/HA-PEG/MDR1 siRNA on Pgp expression. SKOV-3TR cells were incubated with different
agents indicated. (C). Densitometric quantification data from Western blot results. Means 6 SEM were shown. Data are presented as means 6 SEM
and analyzed using Student’s t-test. * P , 0.05, *** P , 0.005.
www.nature.com/scientificreports
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pressed in metastatic ovarian cancer cells than the cells isolated from
primary tumors45. Combined treatment with a nanoscale-based drug
delivery system for paclitaxel, CD44 siRNA led to the suppression of
CD44mRNA and protein expression, efficient induction of cell death,
and effective tumor shrinkage45. In this study, we tested HA-PEI/HA-
PEG CD44 targeted nanoparticle forMDR1 siRNA in ovarian cancer
MDR cells with anticipation that this delivery system will result in
the lowering of the apoptotic threshold necessary for augmenting the
efficacy of paclitaxel in a MDR ovarian cancer model. MDR1 siRNA
was efficiently encapsulated in HA-PEI/HA-PEG nanoparticles and
transfected cells showed significant decreased MDR1 expression. The
resulting delivery system was initially evaluated in human ovarian
cancer MDR cell line SKOV-3TR cell cultures and shown to reverse
resistance to paclitaxel. Furthermore, we evaluated for therapeutic
efficacy in tumor-bearing SKOV-3TR mouse model. Aqueous solu-
tions and HA-PEI/HA-PEG nanoparticle formulations with MDR1
siRNA, non-specific siRNA, and paclitaxel were administered in
combination via the tail vein to tumor-bearing mice. We showed that
the average tumor volume in mice administrated with the combina-
tion of HA-PEI/HA-PEG/MDR1 siRNA CD44 targeted nanoparticle
and paclitaxel was significantly smaller than that observed in control
groups. We then observed that combined HA-PEI/HA-PEG/MDR1
siRNA CD44 targeted nanoparticle and paclitaxel treatment de-
creased Pgp expression and increased apoptosis in MDR cells in
tumor tissues from tumor-bearing mice.
In the current study, human ovarian cancer cell line SKOV-3TR
was used as amodel of drug resistant ovarian cancer cells. There were
several reasons we used SKOV-3TR cells. First, SKOV-3 is one of the
best characterized ovarian cancer cell lines, and the resistant variant
of SKOV-3, SKOV-3TR, is also a well known drug resistant ovarian
cancer cell lines. Both of these cell lines have been widely used in
studies focusing on ovarian cancer drug resistance50–52. Secondly, in
the current study,MDR1 siRNAwas used to knockdown the express-
ion ofMDR1 and corresponding Pgp. It has been demonstrated that
drug resistant ovarian cancer cell line SKOV-3TR overexpresses
MDR1 and Pgp, which is one of the important foundations of using
our HA-based nanoparticle system22,53,54. Thirdly, HA can innately
recognize CD44, and therefore allow for targeted delivery of HA-
based MDR1 siRNA nanoparticles into cells. As shown in the results
of the present study, SKOV-3TR cells displayed higher expression
level of CD44 than the parent SKOV-3 cells. HA-PEI/HA-PEG nano-
particles also successfully delivered MDR1 siRNA into another drug
resistant ovarian cancer cell line, OVCAR8TR. Interestingly, SKOV-
3/SKOV-3TR cells are p53 null cells, while OVCAR8/OVCAR8TR
cells express mutated p53. However, similar effects of HA-PEI/HA-
PEG/MDR1 siRNA on reversing paclitaxel resistance were obtained
Figure 4 | In vivo efficacy of the co-administeredHA-PEI/HA-PEG/MDR1 siRNA and paclitaxel treatment on resistant tumor growth. (A). Treatment
scheme of SKOV-3TRmodel was listed. The day that treatment was initiated was defined as day 1. Themice were treated with either saline,MDR1 siRNA,
non-specific siRNA encapsulated in HA-PEI/HA-PEG orMDR1 siRNA encapsulated in HA-PEI/HA-PEG at a dose of 0.5 mg/kg on day 1, day 2 and day
3. On day 5, all groups were followed with paclitaxel (20 mg/kg) treatment twice a week for two weeks. The tumors were collected on day 33. (B). The
tumor growth curve of mice bearing xenografts of human ovarian cancer multidrug resistant cells SKOV-3TR. Mice were administrated with drugs
indicated. The tumors volume (Vt, mm
3) was measured regularly twice a week and calculated using the formula (W2 3 L)/2, whereW represented width
and L represented length. The relative tumor volume was calculated using the formula Vt/V0, where V0 was tumor volume at time of treatment starting.
(C). Representative tumors from each groupwere listed. (D).Mice bearing xenografts of human ovarian cancer cells SKOV-3 cells were treated with either
HA-PEI/HA-PEG/non-specific siRNA or HA-PEI/HA-PEG/MDR1 siRNA nanoparticles followed with paclitaxel. HA-PEI/HA-PEG/MDR1 siRNA
followed with paclitaxel treatment had no obvious effects on tumor growth in SKOV-3 xenograft model.
www.nature.com/scientificreports
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in these cell lines. These findings indicate that MDR1 siRNA loaded
HA-based CD44 targeted nanoparticles reverse drug resistance in a
p53-independent manner. Our study is consistent with previous
reports suggesting that p53 status does not affect sensitivity of human
ovarian cancer cell lines to paclitaxel55.
In conclusion, our study demonstrated that systemic administra-
tion of HA-PEI/HA-PEG/MDR1 siRNACD44 targeted nanoparticle
and paclitaxel represent an important advance and this strategy can
be effective in enhancing the sensitivity of MDR cells to paclitaxel
and to overcome drug resistance in MDR ovarian cancer.
Methods
Cell culture, reagents and chemicals. MDR ovarian cancer cell lines SKOV3TR,
OVCAR8TR used in this study have been well-characterized previously22,50,56,57.
SKOV-3TR and OVCAR8TR cells were cultured in RPMI 1640 (Life Technologies,
Grand Island, NY) plus 10% fetal bovine serum and 1% penicillin/streptomycin (Life
Technologies, Carlsbad, CA) at 37uC in 5%CO2-95% air atmosphere. The fluorescent
labeled 39-AlexaFluor488 (AF488)-MDR1 siRNA (target sequences: 59-
GAGCTTAACACCCGACTTACATT-39, green color) was obtained from QIAGEN
GmbH (Germany). Two unlabeled siRNAs targeting MDR1 (Genebank Accession
Number NM_00927, 59-GACCAUAAAUGUAAGGUUU-39 and 59-
GAGCUUAACACC CGACUUAUU-39) were purchased separately from Sigma-
Aldrich (St. Louis, MO) and Life Technologies. The non-specific siRNA and
LipofectamineH RNAiMAX were also purchased from Life Technologies Corp. The
monoclonal mouse anti-human Pgp antibody was acquired from Sigma-Aldrich. The
monoclonal mouse anti-human CD44 antibody was purchased form Cell Signaling
Technology (Beverly, MA). Paclitaxel was obtained by the pharmacy at the
Massachusetts General Hospital. HA (MWw20 kDa) was purchased from Lifecore
Biomedical Co. (Chaska, MN). PEI (MW10,000 Da) was obtained from Polysciences
Inc. (Warrington, PA). Mono-functional PEG amine (PEG2k-NH2, MWJ
2000 Da) was purchased from Creative PEG Works (Winston Salem, NC). All the
fatty amines and other reagents for synthesis were purchased from Acros Organics
(Thermo Fisher, Pittsburgh, PA) or Sigma Aldrich Chemical Co (Milwaukee, WI) at
high purity (.99%) and used without further purification.
Synthesis of HA-PEI and HA-PEG derivatives. HA-PEI and HA-PEG were
synthesized as previous described with minor modification32,33. Briefly, HA was
chemically conjugated with PEI dissolved in 5 mL of formamide by warming the
reaction system up to 50uC in a glass scintillation vial. Subsequently, 1-ethyl-3-[3-
dimethylaminopropyl] carbodiimide hydrochloride (EDC) was added into the
reaction mixture and the reaction was then stirred overnight. The resulting solution
was added to a large excess of EtOH (250 mL) to precipitate the polymer. The
precipitate was centrifuged and collected and the washings were discarded. To purify
the polymer, EtOH precipitation and washing was repeated thrice. The precipitate
polymer was finally re-dissolved in deionized water and subjected to ultrafiltration.
Figure 5 | Expression level of Pgp and CD44 in SKOV-3TR mice model. (A) Representative Western blot results were presented. Administration
the combination of HA-PEI/HA-PEG/MDR1 siRNA nanoparticles and paclitaxel dramatically decreased Pgp expression in SKOV-3TR model. CD44
was showed high expression level in SKOV-3TR mice model. Densitometric quantification data fromWestern blot results were presented with mean 6
SEM. *** P , 0.005. (B) Expression level of Pgp and CD44 in mice model was further evaluated by IHC. Histologic analysis of effect of HA-PEI/HA-
PEG/MDR1 siRNA on Pgp staining in ovarian cancer tumor tissues further showed downregulation of Pgp compared with either saline alone, MDR1
alone or HA-PEI/HA-PEG/non-specific siRNA. Representative images were shown.
Figure 6 | The apoptosis level in tumor tissues form mice bearing
xenografts of human ovarian cancer multidrug resistant cells SKOV-
3TR. Mice were administrated with either saline alone,MDR1 siRNA
alone, non-specific siRNA loaded HA-PEI/HA-PEG orMDR1 siRNA
loaded HA-PEI/HA-PEG, and followed with paclitaxel. Paraffin tissue
sections of tumors were processed with the DeadEndTM Colorimetric
TUNEL System. Representative images were shown.
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The concentrated and purified polymer was then lyophilized using a freeze dryer and
stored at 220uC. For the preparation of HA-PEG polymer, HA was chemically
modified with polyethyleneglycol amine (PEG-NH2) using EDC and n-hydroxy sulfo
succinimide (sulfo-NHS). The purified product was also lyophilized and stored at
220uC.
HA-PEI/HA-PEG/MDR1 siRNA nanoparticles preparation and characteristics.
HA-PEI and HA-PEG with same mass were mixed and incubated for 5 min at room
temperature to form self-assembled nanoparticles (HA-PEI/HA-PEG). We previously
optimized the formulation and demonstrated that the highest gene silence efficiency
was achieved when siRNA was encapsulated in HA-PEI/HA-PEG at a mass ratio of
54:1 (polymer : siRNA), therefore, the same ratio of polymer and MDR1 siRNA was
used in the current study32.MDR1 siRNA was mixed with HA-PEI/HA-PEG and then
incubated for another 15 min at room temperature. The particle size and zeta
potentials of the MDR1 siRNA loaded HA-PEI/HA-PEG nanoparticles were
measured with Zetasizer Nano S instrument (Malvern Instuments Ltd,
Worcestershire, UK). Transmission electron micrographs (TEM) of the nanoparticles
was assessed using JEOL JEM-1000 instrument (JEOL Ltd, Tokyo, Japan).
Cell viability analysis. Cytotoxicity of HA-PEI/HA-PEG in SKOV-3TR or
OVCAR8TR cells were assessed byMTT assay. In consideration of the consistency of
the incubation time used in transfection, 5 3 103 cells were seeded in 96-well plate in
triplicate. On the following day, the cells were incubated with HA-PEI/HA-PEG for
6 h and then washed with fresh media to remove HA-PEI/HA-PEG. Subsequently,
cells were cultured with fresh media for another 48 h andMTT assay was conducted.
Briefly, 20 mL MTT (Sigma-Aldrich, St. Louis, MO) was added to each well and
incubated for 4 h. After dissolving the resulting formazan products with acid-
isopropanol, the absorbance was analyzed on a SpectraMax MicroplateH
Spectrophotometer (Molecular Devices LLC, Sunnyvale, CA) at a wavelength of
490 nm. Absorbance values were normalized by assigning the value of the cells in
medium without nanoparticles to 100.
Real-time PCR assay ofMDR1 expression. Real-time PCR was processed to identify
the expression level ofMDR1mRNA in SKOV-3TR or OVCAR8TR cells transfected
with HA-PEI/HA-PEG/MDR1 siRNA according to the manufacturer’s protocol. In
brief, RNA was extracted using Trizol ReagentH (Life Technologies) and reverse
transcribed to cDNA by high capacity cDNA reverse transcription kits (Applied
Biosystems, Foster City, CA). Equal amounts of cDNA were dispersed on the 96-well
plate with the specific TaqManH gene expression assay (Applied Biosystems) and
TaqManH gene expression master mix (Applied Biosystems). The amplifications
were carried out on Applied Biosystems StepOnePlusTM System (Applied
Biosystems). The Comparative CT method was used to analyze the relative MDR1
mRNA expression level.
Western blot assay. Western blot was conducted to determine expression of Pgp in
SKOV-3TR cell line and mouse model. The cells were lysed with 1X RIPA lysis buffer
(Upstate Biotechnology, Charlottesville, VA) supplemented with complete protease
inhibitor cocktail tablets (Roche Applied Science, IN, USA). Protein concentrations
were evaluated by the DC Protein Assay (Bio-Rad, Hercules, USA). Equal amounts of
proteins were separated by NuPAGEH 4–12% Bis-Tris Gel (Life Technologies),
transferred onto nitrocellulose membrane (Bio-Rad), and incubated with specific
primary antibodies (dilution: 151000) at 4uC overnight. After extensive rinsing with
TBST, the membranes were further probed with respective secondary antibodies (LI-
COR Biosciences, Lincoln, NE) at 1520000 dilutions. Finally, the membranes were
scanned using OdysseyH CLx equipment (LI-COR Bioscences) to detect bands. The
density of the bands was then quantified by Odyssey software 3.0 (LI-COR
Bioscences).
Immunofluoresecence assay. In order to further assess the expression levels of CD44
and Pgp in both ovarian cancer parental sensitive cells and multidrug drug resistant
cells, immunofluorescence was performed as previously described58.
Immunostainings were carried out using antibodies against CD44 and Pgp. After
washing the cells, they were incubated with Alexa Fluor secondary antibodies.
Specifically, the slides were stained with Alexa Fluor 594 (Red) conjugated for goat
anti-mouse antibody (Life Technologies) for either CD44 or Pgp. Prior to
microscopy, the nuclei were counter stained with 1 mg/mL Hoechst 33342 (Life
Technologies) for 1 min.
Tumor xenograft model and treatment. To determine the potential effects of the
combination of HA-PEI/HA-PEG/MDR1 siRNA and paclitaxel on tumor growth
inhibition and elucidate underlying mechanisms to overcome MDR in vivo, SKOV-
3TR cells (5 3 106) were suspended in 151 mixture of RPMI 1640 and Matrigel (BD
Biosciences, San Jose, CA), and then injected subcutaneously into Crl:SHO-
PrkdcSCIDHrhr nude female mice at 4-6 weeks age (Charles River Laboratories, Ann
Arbor, MI). Animal procedures were performed according to an approved protocol
byMassachusetts General Hospital Subcommittee on Research Animal Care (SRAC).
The mice were randomized into 4 groups when the tumor volume reached
approximately 200 mm3. The dosing schedule of treatment group was outlined in
Fig 5A. Themice were administered with 0.5 mg/kg eitherMDR1 siRNA loaded HA-
PEI/HA-PEG, non-specific siRNA loaded HA-PEI/HA-PEG,MDR1 siRNA alone or
saline alone on day 1, 2 and 3. All groups were then followed with paclitaxel (20 mg/
kg) treatment twice a week for two weeks beginning on the fifth day. The tumors
volume (Vt, mm3) was measured regularly twice a week and calculated using the
formula (W2 3 L)/2, where W represented width and L represented length. The
relative tumor volume was calculated using the formula Vt/V0, where V0 was tumor
volume at time of treatment commencement. The mice were sacrificed and the
tumors were collected on day 33. Part of tumor tissues were fixed in 4% buffered
formalin and embedded in paraffin for immunohistochemistry staining and TUNEL
apoptosis assay. Another part of tumor tissue was stored at 280uC for extraction of
protein to examine the Pgp and CD44 expression levels.
Immunohistochemistry. Immunohistochemistry was performed in an ovarian
cancer tissue microarray (TMA)54 and in mice tumor tissues by using an
Immunohistochemistry Protocol (Paraffin) and reagents from Cell Signaling
Technology to detect the expression level of Pgp and CD44. Briefly, paraffin tissue
sections from excised tumors were deparaffinized and hydrated through xylene and
graded alcohol. Antigens were unmasked by heat treatment and endogenous
peroxidase was inhibited by incubating with 3%H2O2 for 10 min. After blocking each
section with blocking solution (Cell Signaling Technology) for 1 h at room
temperature, they were incubated with primary antibody in a humidified chamber at
4uC overnight. Sections were then washed with TBST, and the signal were developed
using SignalStainH Boost Detection Reagent (Cell Signaling Technology) and
SignalStainHDAB (Cell Signaling Technology). Finally, the slides were mounted with
VectaMount AQ (Vector Laboratories).
TUNEL assay. To confirm the apoptosis level of tumor in mice, paraffin tissue
sections of tumors were processed with the DeadEndTM Colorimetric TUNEL System
(Promega, Madison, WI) according to the manufacturer’s protocol.
Statistics. The statistical analysis was done using Prism 5.0 software (Graph Pad
Software Inc., SanDiego, CA). The data were expressed asmean6 SEM and analyzed
using two-tailed Student t-test or one-way ANOVA followed byNewman–Keuls post
hoc test. Differences were considered statistically significant at P , 0.05.
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